With Prevail Acquisition, Lilly Plans New Gene Therapy Program
Eli Lilly has announced an agreement to acquire biotechnology company Prevail Therapeutics. Following the deal, Lilly plans to create a gene therapy program for people with neurodegenerative diseases, including Parkinson’s. “The acquisition of Prevail will bring critical technology and highly skilled teams to complement our existing expertise at Lilly,…